ArticlePatient preference and adherence2025
Medication Adherence in Parkinson's Disease: Longitudinal Changes and the Influence of Depressive Symptoms.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Parkinson's disease (PD) is a progressive neurodegenerative disease. As the disease progresses, medication regimens become increasingly complex. The long-term success of PD pharmacotherapy is highly dependent on patient adherence to the prescribed medication regimen. The aim of this study is to investigate how intentional and unintentional non-adherence evolves over time and to identify PD-related factors that influence these longitudinal changes. These findings may be crucial in developing targeted interventions to improve adherence, particularly in patients who have difficulties with intentional or unintentional non-adherence. Patients and Methods: The sample consisted of 91 people with PD who were initially treated as part of the PD multimodal complex treatment at the Department of Neurology, Jena University Hospital, Germany. They were followed up three and six months after discharge. Medication adherence was assessed using the Stendal Adherence to Medication Score (SAMS) and its three subscores for forgetfulness, knowledge, and modification. Statistical analyses included Wilcoxon signed rank test, Friedman test, and generalized estimating equations to determine longitudinal changes in non-adherence and the influence of PD-related variables. Results: Analysis of SAMS subscores showed improvement over time in modification and knowledge, whereas forgetfulness did not show significant change. Modification was significantly associated with depressive symptoms. Conclusion: Medication adherence in PD is a dynamic process and changes over time. The findings suggest that while educational interventions are effective in improving knowledge and reducing intentional non-adherence, addressing depressive symptoms and cognitive impairment is critical to improving overall adherence. Future research should continue to explore the factors that influence adherence behaviors and develop targeted strategies to help people with PD maintain adherence throughout the course of their disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.